Smartphone Sensors to Assess Symptom Relief in Patients With Social Anxiety Disorder Undergoing Treatment
Launched by TEL AVIV UNIVERSITY · Dec 10, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to monitor and reduce symptoms of social anxiety disorder (SAD) using a smartphone app called the BHQ. The researchers want to find out if this app can accurately track feelings of anxiety and if a specific type of training called GC-MRT can help lessen these symptoms compared to traditional methods like questionnaires. Participants in the study will initially meet with a clinician for an interview and complete some questionnaires. They will then use the BHQ app for ongoing monitoring and take part in an attention-training program. After the training, they will have follow-up assessments to see how their symptoms have changed.
To be eligible for this trial, participants need to be between 18 and 65 years old, have a diagnosis of social anxiety disorder, and own a smartphone that can support the app. Certain conditions, such as severe mental health issues or substance abuse, would disqualify someone from participating. Overall, this study is looking to improve the way we understand and treat social anxiety by combining technology with behavioral training.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Normal or corrected vision, without color blindness.
- • A primary diagnosis of social anxiety disorder (based on clinician assessment (LSAS), a MINI interview, and an LSAS score above 50).
- • Age range of 18-65.
- • Ownership of a smartphone that supports the digital monitoring App.
- Exclusion Criteria:
- • Prior experience with GC-MRT.
- • A current diagnosis of post-traumatic stress disorder (PTSD).
- • A current or past diagnosis of psychosis or bipolar disorder.
- • Neurological disorder (e.g., epilepsy, brain injury).
- • Severe suicidal ideation.
- • Substance or alcohol addiction.
- • Concurrent treatment (pharmacological or psychosocial).
- • Pregnancy.
- • Insufficient Hebrew proficiency (unable to complete a clinical interview and/or self-report symptoms and/or perform cognitive tasks).
About Tel Aviv University
Tel Aviv University (TAU) is a leading research institution in Israel, renowned for its commitment to advancing knowledge and innovation across various fields, including medicine and biomedical research. With a strong emphasis on interdisciplinary collaboration, TAU conducts cutting-edge clinical trials aimed at improving healthcare outcomes and developing novel therapeutic strategies. The university's robust network of researchers, state-of-the-art facilities, and partnerships with healthcare organizations enable it to contribute significantly to the global medical research community, fostering advancements that address critical health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tel Aviv, , Israel
Patients applied
Trial Officials
Yair Bar-Haim, Professor
Principal Investigator
School of Psychological Sciences and Sagol School of Neuroscience, Tel Aviv University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported